Status:
RECRUITING
Molecular Characterization for Understanding Biliary Atresia
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Biliary Atresia
Eligibility:
All Genders
Phase:
NA
Brief Summary
Although considered a rare disease, Biliary Atresia (BA) is the leading cause of neonatal cholestasis and liver transplantation in children. Little is known about the molecular mechanisms that drive B...
Detailed Description
Biliary atresia (BA) is a disease characterized by intra- and extra-hepatic bile duct obstruction diagnosed in the neonatal period. If left untreated, this obstruction leads to biliary cirrhosis and e...
Eligibility Criteria
Inclusion
- confirmed diagnosis of biliary atresia in patients
- parents of BA patients
Exclusion
- no
Key Trial Info
Start Date :
February 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 7 2032
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04272515
Start Date
February 7 2021
End Date
February 7 2032
Last Update
June 4 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Necker enfants malades
Paris, De, France, 75015
2
PRC Inserm
Paris, France, 75013